Literature DB >> 30305117

Correction to: Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.

Sara Castiglia1, Aloe Adamini2, Deborah Rustichelli2, Laura Castello2, Katia Mareschi2,3, Giuseppe Pinnetta2, Marco Leone2, Alessandra Mandese2, Ivana Ferrero2,3, Giulia Mesiano4, Franca Fagioli2,3.   

Abstract

Following publication of the original article [1], the authors reported that all of the authors' names were processed incorrectly so that their given and family names were interchanged. In this Correction the correct author names are shown. The original publication of this article has been corrected.

Entities:  

Year:  2018        PMID: 30305117      PMCID: PMC6178249          DOI: 10.1186/s12967-018-1656-7

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


Correction to: J Transl Med (2018) 16:237 10.1186/s12967-018-1613-5

Following publication of the original article [1], the authors reported that all of the authors’ names were processed incorrectly so that their given and family names were interchanged. In this Correction the correct author names are shown. The original publication of this article has been corrected. The correct names are: Sara Castiglia, Aloe Adamini, Deborah Rustichelli, Laura Castello, Katia Mareschi, Giuseppe Pinnetta, Marco Leone, Alessandra Mandese, Ivana Ferrero, Giulia Mesiano and Franca Fagioli.
  1 in total

1.  Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.

Authors:  Sara Castiglia; Aloe Adamini; Deborah Rustichelli; Laura Castello; Katia Mareschi; Giuseppe Pinnetta; Marco Leone; Alessandra Mandese; Ivana Ferrero; Giulia Mesiano; Franca Fagioli
Journal:  J Transl Med       Date:  2018-08-29       Impact factor: 5.531

  1 in total
  1 in total

1.  Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.

Authors:  D Sangiolo; G Valabrega; S Capellero; J Erriquez; C Melano; G Mesiano; S Genta; A Pisacane; G Mittica; E Ghisoni; M Olivero; M F Di Renzo; M Aglietta
Journal:  Sci Rep       Date:  2020-04-15       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.